3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
ponatinib
4
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Imatinib Mesylate
2
Cyclophosphamide
2
Busulfan
2
Bone Marrow Transplantation
2
trametinib
1
ruxolitinib
1
nilotinib
1
dabrafenib
1
cobimetinib
1
bosutinib
1
Vemurafenib
1
CPI-0610
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
BID protein, human
×
Myeloid
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts